Pharmacogenetics in Italy: current landscape and future prospects

Area of Science:

• Pharmacogenetics
• Genomics
• Personalized Medicine

Background:

• Pharmacogenetics uses genetic sequences to tailor drug responses, enhancing personalized medical care.
• Guidelines support genotype-driven drug administration for over 120 substances.
• Growing factors include accessible genotypes, lower sequencing costs, and large genetic studies.

Purpose of the Study:

• To review obstacles and solutions for implementing pharmacogenetic testing in Italian clinical practice.
• To emphasize germline testing due to a lack of national directives.

Main Methods:

• Literature review of pharmacogenetic implementation strategies.
• Analysis of factors influencing genotype-tailored therapy adoption.
• Focus on germline pharmacogenetics within the Italian healthcare context.

Main Results:

• The scientific community increasingly favors genotype-tailored therapy over traditional methods.
• Regulatory bodies like EMA and AIFA provide genotype data but lack clear clinical testing guidelines.
• Implementation is hindered by the absence of well-defined national directives for germline testing.

Conclusions:

• Implementing pharmacogenetics in Italy requires addressing regulatory and practical challenges.
• Clear national directives are essential for the effective integration of germline pharmacogenetic testing.
• Overcoming these obstacles will advance personalized medication and improve patient outcomes.